Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Yamamoto, K.
Right arrow Articles by Nagata, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, K.
Right arrow Articles by Nagata, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 30:446-449 (2000)
© 2000 Foundation for Promotion of Cancer Research

Treatment with Paclitaxel Alone Rather than Combination with Paclitaxel and Cisplatin May be Selective for Cisplatin-resistant Ovarian Carcinoma

Kenji Yamamoto, Yoshihiro Kikuchi, Kazuya Kudoh, Junko Hirata, Tsunekazu Kita and Ichiro Nagata+

Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan

Background: We have previously reported that paclitaxel (taxol) results in cisplatin sensitization to human ovarian cancer cells with cisplatin resistance in vitro. This study was designed to determine effects of taxol and its combination with cisplatin on growth of cisplatin-sensitive cell line (KF28) and the cisplatin-resistant counterpart (KFr13) in nude mice.

Methods: From 14 days after tumor inoculation treatment was initiated. Taxol (3 mg/kg) and cisplatin (2 mg/kg) were administered i.p. once a week for 5 weeks.

Results: In nude mice bearing cisplatin-sensitive cells (KF28), taxol followed by cisplatin and cisplatin plus taxol inhibited significantly (P < 0.05) the tumor growth rate compared with that in nude mice treated with cisplatin alone or taxol alone and cisplatin followed by taxol. On the other hand, in nude mice bearing cisplatin-resistant KFr13 cells, treatment with taxol alone inhibited completely the tumor growth rate, whereas no schedule-dependent interaction of taxol with cisplatin was observed.

Conclusion: These results suggest that treatment with taxol alone may be superior to combination of taxol with cisplatin in patients with cisplatin-resistant ovarian carcinoma.

+ For reprints and all correspondence: Yoshihiro Kikuchi, Department of Obstetrics and Gynecology, National Defense Medical College, Namiki 3–2, Tokorozawa, Saitama 359-8513, Japan. E-mail: qwl04765@nifty.ne.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 RadiologyHome page
C. J. Yoon, J. W. Chung, J. H. Park, Y. H. Yoon, J. W. Lee, S. Y. Jeong, and H. Chung
Transcatheter Arterial Chemoembolization with Paclitaxel-Lipiodol Solution in Rabbit VX2 Liver Tumor
Radiology, October 1, 2003; 229(1): 126 - 131.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.